Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica

NCT06172361

Status	RECRUITING
Phase	Phase 3
Sponsor	Zhejiang University
Enrollment	98 participants

Key Eligibility Criteria

Inclusion (5)

- PMR patients who fulfilled the 1982 Chuang criteria or 2012ACR/EULAR criteria for PMR; They did not receive any glucocorticoids or biological agents during the 2 weeks period that preceded their inclusion in the study;
- Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS (Table 3) \> 10,
- Adults age 50-88, Weight 45-85Kg,
- ESR\>20mm/h or CRP \>50mg/L (5mg/dl),
- Informed consent.

Exclusion (15)

- Patients with known allergies to tofacitinib, prednisone or methylprednisolone,
- Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
- Patients with severe osteoarthritis,
- Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
- Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,

... and 10 more (see full listing online)

Locations (1 total)

Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China